International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn:
“Interim results from the ESAONA trial, presented by Dr. Yuankai Shi, revealed that asandeutertinib demonstrated significant improvements in iORR and iPFS compared with osimertinib as a first-line treatment in patients with EGFR-mutant NSCLC with brain metastases.
Read the highlights from ASCO26 in ILCN.”
Other articles from IASLC on OncoDaily.